Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia

American Journal of Hematology

Volumn 90, Issue 5, 2015, Pages E94-E95

  Jansen, Arend Jan Gerard ^a,b   Peng, Jun ^c,d   Zhao, Hong Guo ^e   Hou, Ming ^c,d   Ni, Heyu ^f,g,h,i  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c SHANDONG UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^f Toronto Platelet Immunobiology Group   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE; ENZYME INHIBITOR; N ACETYLNEURAMINIC ACID;

DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INFLUENZA; LETTER; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; INFLUENZA, HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; THROMBOCYTE; VIROLOGY;

BLOOD PLATELETS; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; OSELTAMIVIR; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84928273689     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23953     Document Type: Letter

References (11)

1. Grozovsky R, Jurak Begonja A, Liu K, et al. The Ashwell-morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015;21:47-54.
2. Jansen AJG, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbα metalloproteinase-mediated cleavage in mice. Blood 2012;119:1263-1273.
3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
4. Neunert C, Lim W, Crowther M, et al. The american society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
5. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost 2014;12:497-504.
6. Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets 2014;28:1-3.
7. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies. Blood 2006;108:943-946.
8. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbα antibodies. Am J Hematol 2012;87:206-208.
9. Jansen AJG, Swart RM, te Boekhorst PAW. Thrombopoietin-receptor agonist for immune thrombocytopenia. N Engl J Med 2011;365:2240-2241.
10. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014;Art. No. CD008965. DOI: 10.1002/14651858.CD008965.pub4.
11. Alioglu B, Tasar A, Ozen C, et al. An experience of oseltamivir phosphate (tamiflu) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: A case report. Pathophysiol Haemost Thromb 2010;37:55-58.